3.57MMarket Cap-604P/E (TTM)
3.089High2.682Low124.46KVolume2.970Open3.210Pre Close367.44KTurnover15.83%Turnover RatioLossP/E (Static)1.21MShares12.00052wk High2.09P/B2.32MFloat Cap2.24052wk Low--Dividend TTM786.30KShs Float61.760Historical High--Div YieldTTM12.69%Amplitude2.240Historical Low2.952Avg Price1Lot Size
Lipella Pharmaceuticals Stock Forum
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals (Nasdaq: LIPO) announced the issuance of U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform. The patent, titled 'Delivery of Agents Using Metastable Liposomes,' extends market exclusivity for the company's lead clinical assets, LP-10and LP-310, currently in Phase 2 trials. LP-10 is a li...
Lipella Pharmaceuticals Will Be Issued U.S. Patent Number 12,138,345 Tomorrow Titled "DELIVERY OF AGENTS USING METASTABLE LIPOSOMES (FOR THE TREATMENT OF BLADDER CONDITIONS
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) (the "Company," "our" or "us"), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 202...
No comment yet